

Journal of Visualized Experiments

Assays for Specific Growth Rate and Cell-Binding Ability of Rotavirus

--Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE58821R3
Full Title:	Assays for Specific Growth Rate and Cell-Binding Ability of Rotavirus
Keywords:	rotavirus; MA104 cell line; specific growth rate; cell binding ability; plaque assay; RT-qPCR
Corresponding Author:	Daisuke Sano Tohoku University Sendai, Miyagi JAPAN
Corresponding Author's Institution:	Tohoku University
Corresponding Author E-Mail:	daisuke.sano.e1@tohoku.ac.jp
Order of Authors:	Syun-suke Kadoya Daisuke Sano
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Open Access (US\$4,200)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	Sendai, Miyagi, Japan

TITLE:

Assays for the Specific Growth Rate and Cell-Binding Ability of Rotavirus

AUTHORS AND AFFILIATIONS:

Syun-suke Kadoya¹, Daisuke Sano^{1,2}

¹Department of Civil and Environmental Engineering, Tohoku University, Sendai, Miyagi, Japan

²Department of Frontier Science for Advanced Environment, Graduate School of Environmental Studies, Tohoku University, Sendai, Miyagi, Japan

Corresponding Author:

Daisuke Sano (daisuke.sano.e1@tohoku.ac.jp)

Email addresses of Co-author:

Syun-suke Kadoya (kadotani9@gmail.com)

KEYWORDS:

rotavirus; MA104 cell line; specific growth rate; cell-binding ability; plaque assay; RT-qPCR

SUMMARY:

Here we present two protocols, one for measuring the specific growth rate and the other for the cell-binding ability of rotavirus using the plaque assay and RT-qPCR. These protocols are available for confirming the differences in phenotypes between rotavirus strains.

ABSTRACT:

Rotavirus is the main etiological factor for infantile diarrhea. It is a double-stranded (ds) RNA virus and forms a genetically diverse population, known as quasispecies, owing to their high mutation rate. Here, we describe how to measure the specific growth rate and the cell-binding ability of rotavirus as its phenotypes. Rotavirus is treated with trypsin to recognize the cell receptor and then inoculated into MA104 cell culture. The supernatant, including viral progenies, is collected intermittently. The plaque assay is used to confirm the virus titer (plaque-forming unit: pfu) of each collected supernatant. The specific growth rate is estimated by fitting time-course data of pfu/mL to the modified Gompertz model. In the assay of cell-binding, MA104 cells in a 24-well plate are infected with rotavirus and incubated for 90 min at 4 °C for rotavirus adsorption to cell receptors. A low temperature restrains rotavirus from invading the host cell. After washing to remove unbound virions, RNA is extracted from virions attached to cell receptors followed by cDNA synthesis and reverse-transcription quantitative PCR (RT-qPCR). These protocols can be applied for investigating the phenotypic differences among viral strains.

INTRODUCTION:

RNA viruses form a genetically diverse population, known as quasispecies¹, because of their mutation rate,² which is higher than that of DNA-based organisms. Population structure in quasispecies is affected by the population genetic factors, including mutation, selection pressure,

and genetic drift. Strains within a single genetic lineage may show different phenotypes because of the genetic diversity. For example, Rachmadi *et al.* showed that free chlorine sensitivity was different among murine norovirus strains that originated from a plaque-purified strain S7-PP3³.

Rotaviruses (genus rotavirus in reoviridae family) are non-enveloped ds RNA viruses forming quasispecies². In addition to the population genetic factors described above, genome reassortment affects the genetic diversity of rotavirus because this virus has 11 segmented genomes⁴. Rotaviruses cause diarrhea mainly among infants, and infant deaths in 2013 were estimated about 250 000⁵. Two vaccines are in use in several countries and have been effective in reducing the burden of rotavirus infection, but some researchers are now discussing the presence of vaccine-escape mutants^{6–9}. The characterization of these mutants is important to understand the vaccine-escape mechanisms.

Here, we present protocols for two assays for evaluating the specific growth rate and cell-binding ability of rotavirus in order to understand the phenotypic differences among strains/mutants. The growth curve of rotaviruses has been presented in previous reports¹⁰, but growth parameters such as specific growth rate are not usually measured. A cell-binding assay conducted previously involves the immunofluorescent staining technique¹¹. We show here easier methods of using the plaque assay and RT-qPCR, which allow us to quantitatively discuss the difference in viral phenotypes. These methods are appropriate for the characterization of rotavirus phenotypes and may finally contribute to the construction of new vaccines effective for multiple genotypes.

PROTOCOL:

1. Medium Preparation

1.1) To make a cell culture medium (serum-containing medium), add 4.7 g of Eagle's MEM powder to 500 mL of distilled water. Autoclave at 120 °C for 20 min and let the medium cool to room temperature. Add fetal bovine serum (final concentration: 10%), L-Glutamine (2 mM), Penicillin Streptomycin (1%) and sodium bicarbonate (1.125 g/L). Store at 4 °C for 1 month.

1.2) Prepare the serum-free medium for the virus propagation as described in step 1.1, but without the fetal bovine serum. Store at 4 °C for 1 month.

1.3) For the plaque assay, sterilize 100 mL of Eagle's MEM medium (non-containing phenol red) by autoclaving. Let the medium cool to room temperature, and then add 2% FBS, 2% Penicillin Streptomycin, 4 mM L-Glutamine, and 2.25 g/L NaHCO₃. Store at 4 °C.

1.4) For the plaque assay, sterilize 100 mL of 2.5% agarose gel by autoclave. Prepare the gel the same day the plaque assay is conducted. Store the gel at 47 °C in a water bath.

2. Cell Culture

2.1) Remove a cryotube containing MA104 cell lines from the liquid nitrogen container. Place the

89 cryotube in a water bath at 37 °C to thaw the cells. Add 1 mL of the cell suspension to 20 mL of
90 the serum-containing medium in a T75 flask. Incubate the flask in an incubator at 37 °C and 5%
91 CO₂ for 2 or 3 days.

92
93 Note: The final cell concentration in the suspension is about 10⁶ cells/mL.

94
95 2.2) Once the cell monolayer reaches 80% confluency, remove the supernatant and wash the
96 cells twice with 5 mL of 1x Dulbecco's PBS (phosphate buffered saline).

97
98 2.3) Add 4 mL of 0.05% trypsin-EDTA to the flask and incubate at 37 °C for 5 min to detach the
99 cells from the flask. Transfer the cell suspension to a 15 mL tube and centrifuge at 190 x g for 5
100 min.

101
102 2.4) Discard the supernatant and resuspend the pelleted cells (10⁶ cells) in 1 mL of serum-
103 containing medium prepared in 1.1. Dilute the resuspended cells at 100-fold with the medium.

104
105 2.5) Add 2 or 1 mL of the diluted cell suspension to each well of 6-well (for the plaque assay) or
106 24-well plates (for the cell-binding assay), respectively. Incubate the plates in an incubator at
107 37 °C and 5% CO₂ under the saturated vapor for 2 or 3 days.

108
109 Note: A T75 flask is suitable to collect the time-course samples because the sample volume of
110 the supernatant (1 mL) can be ignored compared to the total supernatant volume (30 mL).
111 Meanwhile, the infectious titer of the virus in each supernatant is measured by the plaque assay,
112 which is usually conducted using a 6-well plate. A 24-well plate is utilized for the cell-binding
113 assay.

114 115 **3. Specific Growth Rate of Rotavirus**

116
117 Note: Rhesus rotavirus (RRV, genotype: G3P[3]) is utilized in this protocol because RRV can
118 rapidly and easily form plaques with MA104 cells.

119
120 3.1) Place a tube containing 1 mL of the virus suspension (10⁷ pfu/mL) in a serum-free medium
121 stored at -80 °C in a water bath at 37 °C to thaw. Add 1 µg/µL trypsin from porcine pancreas to 1
122 mL of the virus suspension (final trypsin concentration is 4 µg/mL) and then vortex. Incubate the
123 virus suspension at 37 °C and 5% CO₂ under the saturated vapor for 30 min.

124
125 Note: Trypsin from the other sources can be used, but the effect on rotavirus infectivity needs to
126 be tested in advance.

127
128 3.2) Dilute the activated virus suspension with a serum-free medium to adjust the multiplicity of
129 infection (MOI) to 0.1 pfu/cell.

130
131 3.3) Add 1 mL of diluted virus suspension to MA104 cell lines (80% confluent) in a T75 flask 3 days
132 after the cell plating (2.1), incubate at 37 °C for 1 h, and gently shake the flask every 15 min.

133
134 3.4) Then, add 30 mL of a serum-free medium containing 4 µg/mL of trypsin from a porcine
135 pancreas to the flask. Incubate the flask at 37 °C and 5% CO₂ under the saturated vapor.

136
137 3.5) Collect 1 mL of the supernatant in the flask at 0, 6, 12, 18, 24, and 36 (and/or 48) h post-
138 infection (hpi) and replace the supernatant in the 1.5 mL tubes using a pipette.

139
140 3.6) Conduct the freeze (-80 °C) and melt in a water bath at 37 °C cycle three times. Then
141 centrifuge the tubes at 12,600 x g for 10 min at 4 °C. Collect the supernatant.

142
143 3.7) Filter the supernatant with a distilled 0.2 µm filter to remove the cell fraction. Store the
144 supernatant -80 °C in the refrigerator until applying it to the plaque assay for measuring the virus
145 titer.

146
147 3.8) Place the tubes containing the collected supernatant (step 3.5) in a water bath at 37 °C. Add
148 4 µg/mL trypsin to a 1 mL of 10-fold diluted sample and incubate at 37 °C for 30 min.

149
150 3.9) During the 30-min incubation in 3.8, to begin the plaque assay for measuring the virus titer
151 obtained from time course samples (step 3.5), wash the MA104 cells twice in a 6-well plate with
152 2 mL of 1x PBS after removing the serum-containing medium.

153
154 3.10) Serially dilute the incubated samples with a serum-free medium and inoculate 1 mL of the
155 diluted sample into each well. Incubate the plate for 90 min at 37 °C and 5% CO₂ under the
156 saturated vapor, and gently shake the plate every 15 min.

157
158 3.11) After incubation, remove the inoculum from the 6-well plate. Add 4 µg/mL trypsin to the
159 medium prepared in (step 1.3). Gently but immediately add 3 mL of the medium mixed with
160 agarose gel (the ratio is 1:1) to each well.

161
162 3.12) Keep the plate at room temperature for more than 10 min (until the agarose gel becomes
163 solid) and incubate for 2 days at 37 °C and 5% CO₂ under the saturated vapor.

164
165 Note: Pour the medium mixed with agar from the edge of the well.

166
167 3.13) Add 1 mL of the 0.015% neutral red solution diluted with 1x PBS to each well and incubate
168 at 37 °C and 5% CO₂ under the saturated vapor. Remove the dye after 3 h and incubate for 1 day
169 at 37 °C and 5% CO₂ under the saturated vapor.

170
171 3.14) The next day, count the number of plaques in each well and calculate the pfu/mL. Carefully
172 check the cell confluence before the plaque assay to assure the plaque numbers.

173 174 **4. Cell-binding Assay**

175
176 Note: This protocol is based on Gilling's report¹³.

177
178 4.1) Add 1 µg/µL trypsin from a porcine pancreas to 1 mL of the virus suspension (final trypsin
179 concentration is 4 µg/mL) and then vortex (in the same manner as in 2.1). Dilute the virus
180 suspension with a serum-free medium to adjust the MOI of 1 pfu/cell.

181
182 4.2) Then, wash the MA104 cells twice on 24-well plate with 1 ml of Tris-buffered saline (TBS;
183 2.53 g/L Tris base, 6.54 g/L NaCl, 0.3 g/L KCl, 0.046 g/l Na₂HPO₄ to reach 1 L with distilled water).

184
185 4.3) Inoculate 100 µL of diluted virus suspension to each well of a 24-well plate with cells, and
186 incubate at 4 °C for 90 min, with gentle shaking every 15 min.

187
188 4.4) Remove the virus inoculum and wash the cells twice with 1 mL of TBS. To extract the double-
189 stranded (ds) RNA of the rotavirus, add 140 µL of 1x PBS and 560 µL of the RNA extraction buffer
190 (see **Table of Materials**) to each well. Mix adequately with a pipette (about 10x or until the haze
191 or contaminant of cells in the buffer is not seen).

192
193 4.5) After recovering the double stranded RNA (dsRNA) according to the manufacturer's protocol,
194 place the 1.5 mL tubes containing the dsRNA extract on a heat block at 95 °C for 5 min to denature
195 the dsRNA, and then immediately place the tubes on ice and incubate for more than 2 min.

196
197 4.6) Synthesize the cDNA by using a reverse transcription kit (see **Table of Materials**). Add 4 µL
198 of denatured viral RNA solution to a PCR tube containing 16 µL of mixture (**Table 1**) and mix it
199 carefully with a pipette so as not to generate bubbles. Spin down the tubes.

200
201 4.7) Perform the reverse transcription with a thermal cycler under the condition shown in **Table**
202 **2**. If the cDNA is not used immediately, store the PCR tube containing the cDNA at -20 °C for up
203 to 1 year.

204
205 4.8) Use the primers for quantitative PCR (Forward; 5'-ACCATCTACACATGACCCTC-3', Reverse; 5'-
206 GGTCACATAACGCCCC-3')¹⁴ and a probe inserting a quencher (qPCR Probes; 5'-
207 /FAM/ATGAGCACA/quencher/ATAGTAAAAGCTAACACTGTCAA/TAMRA/-3'), targeting the 963 –
208 1049 region of NSP3 genome segment of rotavirus (ST3 strain, GenBank: X81436).

209
210 Note: Quencher is inserted into the probe designed by Zeng *et al.*¹⁴

211
212 4.9) Dilute the standard plasmid serially (10¹ to 10⁶ copies/mL) with PCR grade water to the qPCR
213 mixture (**Table 3**) and make the master mix (20 µL/sample) for qPCR following **Table 4**.

214
215 4.10) Add 20 µL of the master mix to the well of a 96-well PCR plate, and then mix 5 µL of cDNA
216 samples or 5 µL of the standard plasmid by pipetting 10 times. Start the reaction of the qPCR
217 system according to the conditions shown in **Table 4**.

218
219 4.11) To calculate the rotavirus genome bound to the MA104 cell surface, conduct linear
220 regression between Ct values and the known genome number of a standard plasmid, and

estimate the sample's genome number. Then calculate the ratio of virion numbers binding to cells (G_t) to those in the initial inoculum (G_0).

REPRESENTATIVE RESULTS:

An overview of two protocols for the specific growth rate and cell-binding assay of plaque-purified RRV strains is shown in **Figure 1A** and **2A**, respectively.

In the assay for the specific growth rate, the final virus titer reaches more than 10^7 pfu/mL when propagating on the T75 flask. If the maximum concentration is lower than 10^7 pfu/mL, the MA104 cell may not have become confluent or RRV was not activated well by trypsin. Some growth models are available for estimating the specific growth rate using the infectious unit data. In this protocol, the modified Gompertz model¹² is employed as an example;

$$\log \frac{N_t}{N_0} = A \cdot \exp \left\{ - \exp \left[\frac{\mu e}{A} (\lambda - t) + 1 \right] \right\}$$

where N_0 (10^4 pfu/mL in this study) and N_t (10^4 to 10^8 pfu/mL) are the virus infectious titer (pfu/mL) at 0 and t (example: 0, 6, 12, 18, 24, 36) hpi, respectively, A is the asymptotic value [$\log(N_\infty/N_0)$] (example: 3 to 4), μ is the specific growth rate [1/h], e is the Napier's constant and λ is the lag period [h]. Model parameters are obtained by the solver function of the analysis software, which minimizes the sum of squares of the difference between the observed and modeled values. In the example in **Figure 1B**, the specific growth rate (μ) is estimated to be 0.197 [1/h] and the lag period (λ) is 6.61 [h] by applying the least square method to a modified Gompertz model, and the relative virus titer at the stationary phase to the initial titer (log scale) (A) is 3.15 [$\log(N_\infty/N_0)$]. We have tested 6 rotavirus clones in total, and the estimated values of the specific growth rate ranged from 0.19 to 0.27 [1/h]. These estimated values are reliable because the coefficient of determination values in the model fitting is more than 0.98.

RRV virions binding to cell surfaces were about 10^3 copies/mL (binding efficiency was around 1 %) when using a 24-well plate for the cell-binding assay (**Figure 2B**). The assay is usually conducted three times for every sample, and if a large variance in the copy number is observed in a sample, some problems such as over-washing and insufficient activation of RRV by trypsin may occur. The Ct value of qPCR exceeding about 36.0 is not preferable and is regarded to be below a detection limit in our qPCR condition.

TABLE AND FIGURE LEGENDS:

Table 1: Master mix composition for cDNA synthesis of rotavirus genome

Table 2: Reaction condition for cDNA synthesis of rotavirus genome

Table 3: Master mix composition for quantitative PCR of rotavirus A genome

Table 4: Reaction condition for quantitative PCR of rotavirus A genome

Figure 1: Schematic overview of the estimation of rotavirus growth and the growth curve of rotavirus. A) The infectious unit of rotavirus is measured with the plaque assay. B) The curve (blue line) was approximated by the modified Gompertz model based on observed data in our laboratory (white circle). The specific growth rate $[\mu]$; 0.197 $[h^{-1}]$, lag period (λ) ; 6.61 $[h]$, the relative virus titer at the stationary phase to the initial titer (log scale) (A); 3.15 $[\log (N_{\infty}/N_0)]$.

Figure 2: Schematic overview and representative result of the cell-binding assay of five RRV strains purified from plaques in our laboratory. A) A cell culture plate inoculated with rotavirus is incubated at 4 °C for inhibiting the virus invasion into cells. After incubation and removing the unbound viral particles to cells, quantify the number of genomes originating from bound viral particles to the cell surface with RT-qPCR. B) The result of the cell-binding assay was displayed as binding efficiency (%), which was the ratio of bound viral particles to those present in the inoculum. Bold bar: median, end of boxes: quartile deviation, end of line: maximum and minimum.

DISCUSSION:

Our protocol for measuring the specific growth rate is easier than previous ones and can be adapted for other viruses unless their cell culture system has not yet been established. In this study, we used RRV (G3P[3]) because this strain can form plaques easier than human rotaviruses when using MA104 cell lines. Some human rotavirus strains cannot form plaque in this cell line. Therefore, instead of the plaque assay, the focus forming unit (FFU) assay¹⁵ or median tissue culture infectious dose (TCID₅₀) assay can be applied for many rotavirus strains¹⁶. The presented protocol for determining the specific growth rate can be used for other virus types but is not suitable for viruses for which no established cell culture system is established. Before starting the experiment for the specific growth rate, it is better to know in advance when the virus infectious titer starts to increase and reaches the stationary phase in a preliminary test. If too many plaques are present, the plaque assay should be conducted again after changing the dilution rate of the virus samples. The hours post-infection (hpi) to collect samples are also important because the slope of the exponential growth phase may be underestimated if the proper time point to reach the stationary phase is missed. In the approximation by the modified Gompertz model, a coefficient of determination should always be calculated and checked. If the fitness to the modified Gompertz model is low, other growth models such as the modified logistic model¹² may be preferable.

In handling cells, when removing the medium or virus inoculum, the PBS for washing or agarose gel for plaque assay must be promptly added to each well of a cell culture plate to prevent the cells from dryness. At the same time, you must gently pour PBS or agarose to cells not to detach from wells. This step is the most important in both assays (step 3.9 and 3.11). If the plaque assay has too many samples, we recommend subdividing the agarose gel (100 mL each maximum is recommended) into several medium bottles and keeping the bottles warm until just before use since agarose gel is solidified within about 10 min at room temperature. Since trypsin is vulnerable to high temperatures¹⁷, a trypsin solution should be added to a medium and agarose

for the plaque assay after adequately cooling down.

In the cell-binding assay, the incubation for virus binding to cells must be done at 4 °C to prevent invasion of the cells. According to Gilling's method¹³, cells are prone to drying at low temperatures, so gentle shaking is necessary every 15 min during incubation. The RNA extraction kit utilized here can be substituted for other kits. The slope of the standard curve in RT-qPCR should be approximately 3.3, and the coefficient of determination should be more than 0.98. Compared to the fluorescence microscope to visualize the localization of viruses in cells, the assay is more rapid and easier to use because binding of fluorescent substances to viruses is not necessary.

Recently, human intestinal enteroid (HIE), exhibiting a similar cellular composition and function as human gastrointestinal epithelium, has become available for rotavirus propagation¹⁸. The use of HIE may enable us to evaluate the specific growth rate and cell-binding ability of non-culturable strains of rotavirus. Also, both experiments described here may be applied to the evaluation of drug effects on both phenotypes¹⁹. The protocols presented here make it possible to quantitatively discuss the changes in phenotype parameter values of rotavirus strains under varied conditions.

ACKNOWLEDGMENTS:

This work was supported by "The Sanitation Value Chain: Designing Sanitation Systems as Eco-Community Value System" Project, Research Institute for Humanity and Nature (RIHN, Project No.14200107).



DISCLOSURES:



The authors have nothing to disclose.

REFERENCES:

1. Domingo, E. Rna Virus Mutations. *Annual review of microbiology* **51**, 151–178 (1997).
2. Gouvea, V. & Brantly, M. Is rotavirus a population of reassortants? *Trends in Microbiology*. **3**, 159–162 (1995).
3. Rachmadi, A. T., Kitajima, M., *et al.* Free-chlorine disinfection as a selection pressure on norovirus. *Applied and Environmental Microbiology*. **84**, (2018).
4. Ghosh, S. & Kobayashi, N. Whole-genomic analysis of rotavirus strains: current status and future prospects. *Future Microbiology*. **6**, 1049–1065 (2011).
5. Tate, J. E., Burton, A. H., Boschi-Pinto, C., Steele, A. D., Duque, J. & Parashar, U. D. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: A systematic review and meta-analysis. *The Lancet Infectious Diseases*. **12**, 136–141 (2012).
6. Franco, M. A., Angel, J. & Greenberg, H. B. Immunity and correlates of protection for rotavirus vaccines. *Vaccine*. **24**, 2718–2731 (2006).
7. Santos, N. & Hoshino, Y. Global distribution of rotavirus serotypes/ genotypes and its implication for the development and implementation of an effective rotavirus vaccine. *Reviews in Medical Virology*. **15**, 29–56 (2005).

- 351 8. Matthijssens, J., Heylen, E., Zeller, M., Rahman, M., Lemey, P. & Van Ranst, M.
352 Phylodynamic analyses of rotavirus genotypes G9 and G12 underscore their potential for
353 swift global spread. *Molecular Biology and Evolution*. **27**, 2431–2436 (2010).
- 354 9. Mukhopadhyaya, I., Murdoch, H., *et al.* Changing molecular epidemiology of rotavirus
355 infection after introduction of monovalent rotavirus vaccination in Scotland. *Vaccine*. **35**,
356 156–163 (2017).
- 357 10. Londrigan, S. L., Hewish, M. J., Thomson, M. J., Sanders, G. M., Mustafa, H. & Coulson, B.
358 S. Growth of rotaviruses in continuous human and monkey cell lines that vary in their
359 expression of integrins. *Journal of General Virology*. **81**, 2203–2213 (2000).
- 360 11. Hewish, M. J., Takada, Y. & Coulson, B. S. Integrins a2b1 and a4b1 can mediate SA11
361 rotavirus attachment and entry into cells. *Journal of Virology*. **74**, 228–236 (2000).
- 362 12. MH Zwietering, Il Jongenburger, FM Rombouts, K. V. R. Modeling of the bacterial growth
363 curve. *Applied and Environmental Microbiology*. **56**, 1875–1881 (1990).
- 364 13. Gilling, D. H., Kitajima, M., Torrey, J. R. & Bright, K. R. Mechanisms of antiviral action of
365 plant antimicrobials against murine norovirus. *Applied and Environmental Microbiology*.
366 **80**, 4898–4910 (2014).
- 367 14. Zeng, S. Q., Halkosalo, A., Salminen, M., Szakal, E. D., Puustinen, L. & Vesikari, T. One-step
368 quantitative RT-PCR for the detection of rotavirus in acute gastroenteritis. *Journal of*
369 *Virological Methods*. **153**, 238–240 (2008).
- 370 15. Rolsma, M. D., Gelberg, H. B. & Kuhlenschmidt, M. S. Assay for evaluation of rotavirus-
371 cell interactions: identification of an enterocyte ganglioside fraction that mediates group
372 A porcine rotavirus recognition. *Journal of Virology*. **68**, 258–68 (1994).
- 373 16. Brüssow, H., Hilpert, H., Walther, I., Sidoti, J., Mietens, C. & Bachmann, P. Bovine milk
374 immunoglobulins for passive immunity to infantile rotavirus gastroenteritis. *Journal of*
375 *Clinical Microbiology*. **25**, 982–986 (1987).
- 376 17. Outzen, H., Berglund, G. I., Smalås, A. O. & Willassen, N. P. Temperature and pH
377 sensitivity of trypsins from Atlantic salmon (*Salmo salar*) in comparison with bovine and
378 porcine trypsin. *Comparative Biochemistry and Physiology - B Biochemistry and*
379 *Molecular Biology*. **115B**, 33–45 (1996).
- 380 18. Saxena, K., Blutt, S. E., *et al.* Human intestinal enteroids : a new model to study human
381 rotavirus infection , Host Restriction , and Pathophysiology. **90**, 43–56 (2016).
- 382 19. Yin, Y., Bijvelds, M., *et al.* Modeling rotavirus infection and antiviral therapy using
383 primary intestinal organoids. *Antiviral Research*. **123**, 120–131 (2015).
- 384





Volume/ 1 reaction	
5 x PrimeScript Buffer	4.0 µL
PrimeScript RT Enzyme Mi	1.0 µL
Oligo dT Primer	1.0 µL
Random 6 mers	4.0 µL
Deionized distilled water	6.0 µL
ssRNA sample	4.0 µL
Total	20.0 µL

Temperature [°C]	Time
37	15 min
42	15 min
85	5 s
4	∞

Volume/ 1 reaction	
Premix Taq	12.5 µL
Forward primer (10 µM)	0.5 µL
Reverse primer (10 µM)	0.5 µL
Probe (10 µM)	0.5 µL
Reference Dye II	0.5 µL
Deionized distilled water	5.5 µL
cDNA sample	5.0 µL
Total	25 µL

Temperature [°C]	Time	
95	5 min	
94	20 s	} 45 cycle
60	1 min	
72	5 min	

Name of Material / Equipment	Company
7500 Real Time PCR System	Applied Biosystems
Agar-EPI	Nakalai Tesque, Inc
Disodium Hydrogenphosphate	Wako Pure Chemical Corporation
Eagle's MEM "Nissui" ①	Nissui Pharmaceutical Co., Ltd
Eagle's MEM "Nissui" ②	Nissui Pharmaceutical Co., Ltd
EasYFlask 75 cm ²	Thermo Scientific
Fetal bovine Serim, qualified, USDA-approved regions	Gibco
Forward / Reverse primers	Eurofins Genomics
L-Glutamine, 200 mM Solution	Gibco
Neutral Red	Wako Pure Chemical Corporation
PBS (-) "Nissui"	Nissui Pharmaceutical Co., Ltd
Penicillin-Streptomycin, Liquid	Gibco
Potassium Chloride	Wako Pure Chemical Corporation
Premix ExTaq (Perfect Real Time)	TAKARA Bio Inc.
PrimeScript TM RT reagent Kit (Perfect Real Time)	TAKARA Bio Inc.
PrimeTime qPCR Probes	Medical and Biological Laboratories Co., Ltd.
QIAamp Viral RNA Mini Kit	QIAGEN
Sodium Bicarbonate	Wako Pure Chemical Corporation
Sodium Chloride	Wako Pure Chemical Corporation
Tissue culture plates 24-well plate	TPP
Tissue culture plates 6-well plate	TPP
Trizma base	SIGMA-ALDRICH
Trypsin from porcine pancreas	SIGMA-ALDRICH
Trypsin-EDTA (0.05 %), phenol red	Gibco
Vertical 96-Well Thermal Cycler	Applied Biosystems

Catalogue Number	Comments / Description
	qPCR
01101-34	Plaque assay
194-02875	Cell binding assay
_05900	Cell culture
_05901	Plaque assay
156499	Cell culture
10437028	Cell culture and Plaque assay
	qPCR
2530081	Cell culture and Plaque assay
140-00932	Plaque assay
_05913	Cell culture and Plaque assay
15140122	Cell culture and Plaque assay
163-03545	Cell binding assay
RR039A	qPCR
RR037A	cDNA synthesis
	qPCR
52904	RNA extraction
199-05985	Cell culture and Plaque assay
198-01675	Cell binding assay
92024	Cell binding assay
92006	Plaque assay
T1503	Cell binding assay
T0303-1G	Activate for rotavirus
25300054	Cell culture
	cDNA synthesis



1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

Assays for Specific Growth Rate and Cell Binding Ability of Rotaviruses

Author(s):

Syun-suke Kadoya, Daisuke Sans

Item 1 (check one box): The Author elects to have the Materials be made available (as described at <http://www.jove.com/author>) via: ☐ Standard Access ☒ Open Access

Item 2 (check one box):

- ☒ The Author is NOT a United States government employee.
- ☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.
- ☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: **"Agreement"** means this Article and Video License Agreement; **"Article"** means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; **"Author"** means the author who is a signatory to this Agreement; **"Collective Work"** means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; **"CRC License"** means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; **"Derivative Work"** means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; **"Institution"** means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; **"JoVE"** means MyJoVE Corporation, a Massachusetts corporation and the publisher of *The Journal of Visualized Experiments*; **"Materials"** means the Article and / or the Video; **"Parties"** means the Author and JoVE; **"Video"** means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4 and 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. Retention of Rights in Article. Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. Grant of Rights in Video – Standard Access. This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. Grant of Rights in Video – Open Access. This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. Government Employees. If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such

statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. Likeness, Privacy, Personality. The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

9. Author Warranties. The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

10. JoVE Discretion. If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have

ARTICLE AND VIDEO LICENSE AGREEMENT

full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's

expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

12. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

13. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.

CORRESPONDING AUTHOR:

Name: Daisuke Sano
Department: Department of Frontier Science for Advanced Environment
Institution: Tohoku University
Article Title: Assays for Specific Growth Rate and Cell Binding Ability of Rotavirus
Signature: 1/2 野 大輔 Date: July 25, 2018

Please submit a signed and dated copy of this license by one of the following three methods:

- 1) Upload a scanned copy of the document as a pdf on the JoVE submission site;
- 2) Fax the document to +1.866.381.2236;
- 3) Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02139

For questions, please email submissions@jove.com or call +1.617.945.9051

Reply to EDITOR

Line34: Cells are infected with virus.

Response: Modified as suggested (lines 34-35).

Line35-36: This part needs clarity.

Response: Modified for clarity (lines 35-36).

Line37-38: Reworded please check

Response: Checked but modified (RNA is extracted from virions attached to cell receptors, line 37).

Line61: ...conducted previously involves the immunofluorescence staining technique.

Response: Modified as suggested (lines 61-62).

Line68: Please highlight 2.75 pages or less of the Protocol (including headings and spacing)

that identifies the essential steps of the protocol for the video, i.e., the steps that should be visualized to tell the most cohesive story of the Protocol. The highlighted steps should form a cohesive narrative with a logical flow from one highlighted step to the next.

Response: A Word file for the highlight of the protocol is attached.

Line97: Do you count the cells before plating? If yes include a step stating the same.

Response: We do not count the cells here, so the sentence was removed.

Line104: What is the volume and amount of virus.

Response: Added the volume and amount information (line 117).

Line113: Of or to?

Response: “To” is correct (line 126).

Line114: Adding this for clarity.

Response: Checked it (line 127).

Line120: Replace where and how?

Response: Modified. Supernatant is replaced to 1.5 ml tube by a pipet (line 133).

Line121: Store the supernatant.

Response: Modified as suggested (lines 135-136).

Line123-124: So you are storing the supernatant at -80 Degrees in the step 3.3. Which

tubes are mentioned in this case? Please be as specific as you can. Maybe include a step

before 3.4 to collect the cells and centrifuge. Also after how long is this collection being

performed.

Response: These are the tubes containing the collected supernatant in step 3.3 (lines 138-139). Tracing the change in infectious titer of the collected supernatant usually requires collecting only the virions released into the supernatant, because some viruses inside host cells may be un-matured virions, which is why the collection of cells and centrifuge is not needed here.

Line126-129: So in 3.2 you are first infecting the cells in t75 flask and here in 6 well and 24 well plate. Please explain the rationale of doing so.

Response: T75 flask is suitable to collect the time-course samples because the sample volume of the supernatant (1 ml) can be ignored compared to the total supernatant volume (30ml). Meanwhile, the infectious titer of virus in each supernatant is measured by plaque assay, which is usually conducted using a 6-well plate. The 24-well plate is utilized for the cell-binding assay. These were explained in the note on line 106.

Line131-135: All media preparation can be clubbed in the media preparation section. Or do you need to make this fresh?

Response: Added the media preparation section (lines 69-84).

Line137: Is this correct?

Response: Modified for clarity (line 147).

Line144: Diluted by or with also what is the concentration used?

Response: Changed to “with”. 1 x PBS (phosphate buffered saline) is used in this study (line 154).

Line149: ???

Response: Modified and move the sentence to the Discussion section (lines 276-278).

Line152-161: Please use imperative tense or move to the result section.

Response: Agree. Moved to the result and discussion section as suggested (lines 215-227).

Line179: To each well with cells?

Response: Modified as suggested (line 172).

Line183: dsRNA???

Response: ds RNA stands for double-stranded RNA (dsRNA) (line 181).

Line194: Prepare or Use?

Response: Changed to “Use” as suggested (line 192).

Line195: We cannot have commercial language in the manuscript. Please remove the term

taqman

Response: Removed the commercial name (line 193).

Line199: This sentence needs clarity.

Response: Modified for clarity (line 197).